Boundless Bio, Inc.
BOLD · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.01 | -0.00 | -0.00 | 0.00 |
| FCF Yield | -128.67% | -21,353,158.39% | -18,283,821.73% | -11,368,146.70% |
| EV / EBITDA | -1.09 | 0.44 | 0.13 | 1.38 |
| Quality | ||||
| ROIC | -36.95% | -44.65% | -65.05% | -22.87% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.93 | 0.95 | 0.86 | 0.92 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | -33.46% | -16.79% | -60.83% | 0.00% |
| Safety | ||||
| Net Debt / EBITDA | -0.33 | 0.44 | 0.13 | 1.38 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -428.19 | -847.47 | -543.24 | -575.33 |